NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/24/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,152.35 mln
Float93.80 mln
Earnings Date10/29/2026
EPS
0.22
Overpriced
P / E
113
Highly speculative
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
-1.95
Caution advised
1-Year Forecast
36.88
Exceptional upside
Relative Strength
21
/ 100
Significantly lagging
Business Description
Arcutis Biotherapeutics is a California-based company founded in 2016 that researches and brings to market new medicines for skin conditions. Its flagship product, ZORYVE, is available as both a cream and a foam to treat conditions such as plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. The company is also working on an experimental treatment called ARQ-234, which targets the immune system to address skin disease in a novel way.
